Mallinckrodt has signed an agreement to purchase all outstanding shares of Sucampo Pharmaceuticals for around $1.2bn.

Under the agreement, Mallinckrodt will acquire Sucampo’s commercial and development assets, including the US Food and Drug Administration (FDA) approved AMITIZA (lubiprostone), which is a chloride channel activator developed for the treatment of constipation.

In addition, Mallinckrodt will buy the global rights to RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% indicated for ocular hypertension and open-angle glaucoma in Japan.

Sucampo’s development assets include CPP-1X/sulindac and VTS-270, which is in Phase III development for Niemann-Pick type C (NPC).

“Mallinckrodt will acquire Sucampo’s commercial and development assets, including the US Food and Drug Administration (FDA) approved AMITIZA (lubiprostone).”

Being developed under a collaborative agreement with Cancer Prevention Pharmaceuticals (CPP), CPP-1X/sulindac is currently under Phase III development to treat familial adenomatous polyposis (FAP).

Mallinckrodt CEO and president Mark Trudeau said: “The acquisition brings near-term net sales and earnings accretion through AMITIZA and supports our pipeline in rare diseases with VTS-270 and CPP-1X/sulindac.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company intends to leverage Sucampo’s existing commercial footprint for VTS-270 and CPP-1X/sulindac, and will utilise its own clinical and medical affairs infrastructure to support the approval and launch of these products.

Sucampo chairman and CEO Peter Greenleaf said: “With the addition of its significant resources and expertise, we believe Mallinckrodt is a natural partner to accelerate the development of our rare disease assets in NPC and FAP, and to continue to provide AMITIZA for patients suffering from constipation-related disorders.”

Subject to customary closing conditions, the transaction is expected to close in Q1 2018.